Treatment of Parkinson’s disease using cell transplantation

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1680, 2015, Pages

  Lindvall, Olle ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dopaminergic neurons; Neural grafts; Parkinson s disease; Reprogramming; Stem cells; Transplantation

Indexed keywords

CELLS AND CELL COMPONENTS; DISEASE TREATMENT; NERVOUS SYSTEM DISORDER; PHENOTYPE; STANDARDIZATION;

CELL REPROGRAMMING TECHNIQUE; CELL TRANSPLANTATION; DOPAMINERGIC NERVE CELL; EMBRYONIC STEM CELL; FETAL TISSUE TRANSPLANTATION; HUMAN; NEURAL STEM CELL; PARKINSON DISEASE; PROCEDURES; TRANSPLANTATION; TRENDS;

CELL TRANSPLANTATION; CELLULAR REPROGRAMMING TECHNIQUES; DOPAMINERGIC NEURONS; EMBRYONIC STEM CELLS; FETAL TISSUE TRANSPLANTATION; HUMANS; NEURAL STEM CELLS; PARKINSON DISEASE;

EID: 84942912716     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0370     Document Type: Review

References (58)

1. Bjorklund A, Stenevi U. 1979 Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 177, 555-560. (doi:10.1016/0006-8993(79)90472-4)
2. Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ. 1979 Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204, 643-647. (doi:10.1126/science.571147)
3. Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G, Seiger A, Olson L. 1985 Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 62, 169-173. (doi:10.3171/jns.1985. 62.2.0169)
4. Lindvall O, Backlund EO, Farde L, Sedvall G, Freedman R, Hoffer B, Nobin A, Seiger A, Olson L. 1987 Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen. Ann. Neurol. 22, 457-468. (doi:10.1002/ana. 410220403)
5. Madrazo I, Drucker-Colin R, Diaz V, Martmez-Mata J, Torres C, Becerril JJ. 1987 Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N. Engl. J. Med. 316, 831-834. (doi:10. 1056/NEJM198704023161402)
6. Lindvall O. 2013 Developing dopaminergic cell therapy for Parkinson's disease—give up or move forward? Mov. Disord. 28, 268-273. (doi:10.1002/ mds.25378)
7. Freed CR et al. 2001 Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719. (doi:10.1056/ NEJM200103083441002)
8. Olanow CW et al. 2003 A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54, 403-414. (doi:10.1002/ana.10720)
9. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. 2008 Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506. (doi:10.1038/nm1747)
10. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. 2008 Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov. Disord. 23, 2303-2306. (doi:10.1002/mds.22369)
11. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, Snow B, Olanow CW. 1998 Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov. Disord. 13, 383-393. (doi:10.1002/mds.870130303)
12. Kordower JH et al. 1995 Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332, 1118-1124. (doi:10.1056/NEJM19950427 3321702)
13. Kordower JH et al. 1996 Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370, 203-230. (doi:10.1002/(SICI)1096-9861(19960624)370:2<203::AID-CNE6>3.0.GO;2-6)
14. Li JY et al. 2008 Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503. (doi:10.1038/nm1746)
15. Li JY, Englund E, Widner H, Rehncrona S, Bjorklund A, Lindvall O, Brundin P. 2010 Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 25, 1091-1096. (doi:10.1002/mds.23012)
16. Mendez I, Sanchez-Pernaute R, Cooper O, Vinuela A, Ferrari D, Bjorklund L, Dagher A, Isacson O. 2005 Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128,1498-1510. (doi:10.1093/brain/ awh510)
17. Mendez I et al. 2008 Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14, 507-509. (doi:10.1038/nm1752)
18. Piccini P et al. 1999 Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 2, 1137-1140. (doi:10.1038/16060)
19. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P. 2010 Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2, 38ra46. (doi:10.1126/scitranslmed. 3000976)
20. Piccini P et al. 2000 Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann. Neurol. 48, 689695. (doi:10.1002/1531-8249(200011)48:5<689:AID-ANA1>3.0.CO;2-N)
21. Kefalopoulou Z et al. 2014 Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 71, 83-87. (doi:10.1001/jamaneurol.2013.4749)
22. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn, Freed C, Dhawan V, Eidelberg D. 2010 Dopamine cell implantation in Parkinson's disease: long-term clinical and 18F-FDOPA PET outcomes. J. Nucl. Med. 51, 7-15. (doi:10.2967/jnumed.109.066811)
23. Brundin P et al. 2000 Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123, 1380-1390. (doi:10.1093/brain/123.7.1380)
24. Hagell P et al. 1999 Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 122,1121-1132. (doi:10.1093/ brain/122.6.1121)
25. Wenning GK et al. 1997 Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 42, 95-107. (doi:10.1002/ana.410420115)
26. Piccini P, Pavese N, Hagell P, Reimer J, Bjorklund A, Oertel WH, Quinn NP, Brooks DJ, Lindvall O. 2005 Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128, 2977-2986. (doi:10.1093/brain/awh649)
27. Kurowska Z, Englund E, Widner H, Lindvall O, Li J-Y, Brundin P. 2011 Signs of degeneration in 12-22-; year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. J. Parkinson's Dis. 1, 83-92. (doi:10.3233/JPD-2011-11004)
28. Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, Bjorklund A, Lindvall O, Piccini P. 2011 Graft-induced dyskinesias in Parkinson's disease: high; striatal serotonin/dopamine transporter ratio. Mov. Disord. 26, 1997-2003. (doi:10.1002/mds.23743)
29. Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. 2014 Long-term health of dopaminergic j neuron transplants in Parkinson's disease patients. Cell Rep. 7,1755-1761. (doi:10.1016/j.celrep.2014. 05.027)
30. Graff-Radford J, Foote KD, Rodriguez RL, Fernandez HH, Hauser RA, Sudhyadhom A, Rosado CA, Sanchez JC, Okun MS. 2006 Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. Arch. Neurol. 63, 1181-1184. (doi:10.1001/archneur.63.8.1181)
31. Herzog J, Pogarell O, Pinsker MO, Kupsch A, Oertel WH, Lindvall O, Deuschl G, Volkmann J. 2008 Deep brain stimulation in Parkinson's disease following fetal nigral transplantation. Mov. Disord. 23, 1293-1296. (doi:10.1002/mds.21768)
32. Lane EL, Vercammen L, Cenci MA, Brundin P. 2009 Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Exp. Neurol. 219, 355-358. (doi:10.1016/j.expneurol.2009.04.010)
33. Carlsson T, Winkler C, Lundblad M, Cenci MA, Bjorklund A, Kirik D. 2006 Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol. Dis. 21, 657-668. (doi:10. 1016/j.nbd.2005.09.008)
34. Maries E, Kordower JH, Chu Y, Collier TJ, Sortwell CE, Olaru E, Shannon K, Steece-Collier K. 2006 Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol. Dis. 21, 165-180. (doi:10.1016/j.nbd.2005.07.002)
35. Shin E, Garcia J, Winkler C, Bjorklund A, Carta M. 2012 Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. Neurobiol. Dis. 47, 393-406. (doi:10.1016/j.nbd.2012.03.038)
36. Lindvall O, Barker RA, Brustle O, Isacson O, Svendsen CN. 2012 Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell 10, 151-155. (doi:10.1016/j.stem.2012.01.009)
37. Bye CR, Jonsson ME, Bjorklund A, Parish CL, Thompson LH. 2015 Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors. Proc. Natl Acad. Sci. USA 112, E1946-E1955. (doi:10.1073/pnas. 1501989112)
38. Doi D et al. 2014 Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Rep. 2, 337-350. (doi:10. 1016/j.stemcr.2014.01.013)
39. Ganat YM et al. 2012 Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. J. Clin. Invest. 122, 2928-2939. (doi:10.1172/JCI58767)
40. Hedlund E, Pruszak J, Lardaro T, Ludwig W, Vinuela A, Kim KS, Isacson O. 2008 Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells 26, 1526-1536. (doi:10.1634/stemcells.2007-0996)
41. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. 2006 Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12, 1259-1268. (doi:10.1038/nm1495)
42. Kriks S et al. 2011 Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547-551. (doi:10.1038/nature10648)
43. Kirkeby A, Grealish S, Wolf DA, Nelander J, Wood J, Lundblad M, Lindvall O, Parmar M. 2012 Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 1, 703-714. (doi:10.1016/j.celrep.2012.04.009)
44. Steinbeck JA, Choi SJ, Mrejeru A, Ganat Y, Deisseroth K, Sulzer D, Mosharov EV, Studer L. 2015 Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model. Nat. Biotechnol. 33, 204-209. (doi:10.1038/nbt.3124)
45. Grealish S et al. 2014 Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease. Cell Stem Cell 15, 653-665. (doi:10.1016/j.stem.2014.09.017)
46. Hargus G et al. 2010 Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc. Natl Acad. Sci. USA 107, 15 921-926. (doi:10.1073/pnas.1010209107)
47. Kikuchi T, Morizane A, Doi D, Onoe H, Hayashi T, Kawasaki T, Hidemoto S, Susumu M, Jun T. 2011 Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease. J. Parkinson's Dis. 1, 395-412. (doi:10.3233/JPD-2011-11070)
48. Rhee YH et al. 2011 Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J. Clin. Invest. 121, 2326-2335. (doi:10.1172/ JCI45794)
49. Sundberg M et al. 2013 Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety ofhESC, hiPSC, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 31, 1548-1562. (doi:10.1002/ stem.1415)
50. Swistowski A, Peng J, Liu Q, Mali P, Rao MS, Cheng L, Zeng X. 2010 Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells 28, 1893-1904. (doi:10.1002/stem.499)
51. Turner M et al. 2013 Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell 13, 382-384. (doi:10.1016/j.stem.2013. i 08.003)
52. Kokaia Z, Martino G, Schwartz M, Lindvall O. 2012 Cross-talk between neural stem cells and immune j cells: the key to better brain repair? Nat. Neurosci. 15, 1078-1087. (doi:10.1038/nn.3163)
53. Hallett PJ et al. 2015 Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate i model of Parkinson's disease. Cell Stem Cell 16, 269-274. (doi:10.1016/j.stem.2015.01.018)
54. Caiazzo M et al. 2011 Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476, 224-227. (doi:10. 1038/nature10284)
55. Pfisterer U et al. 2011 Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl Acad. Sci. USA 108, 10 343-348. (doi:10.1073/ pnas.1105135108)
56. Kim J et al. 2011 Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell 9, 413-419. (doi:10.1016/j.stem.2011.09.011)
57. Dell'Anno MT et al. 2014 Remote control ofinduced dopaminergic neurons in parkinsonian rats. J. Clin. Invest. 124, 3215-3229. (doi:10.1172/JCI74664)
58. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Bjorklund A, Lindvall O, Piccini 2012 Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci. Transl. Med. 4, 128ra41. (doi:10.1126/scitranslmed.3003391)